Etanercept in childhood psoriasis: An experience from Kuwait

The Gulf Journal of Dermatology and Venereology ABSTRACT Psoriasis commonly affects children and adolescents, and the need for safe, effective therapy is a special consideration in the pediatric population. Recently, the use of biologic agents has been extensively studied for the treatment of psoriasis in adults. Of these, etanercept, a tumor necrosis factor-α antagonist, which FDA has approved for the treatment of psoriasis and psoriatic arthritis in adults, and while it is approved for use in juvenile rheumatoid arthritis, it is the closest to achieve the approval for the treatment of moderately severe plaque psoriasis in children. We present our experience of treating eighteen pediatric patients with generalized, recalcitrant stable plaque psoriasis with etanercept therapy. ORIGINAL ARTICLE